Remission of Invasive, Cancer Stem-Like Glioblastoma Xenografts Using Lentiviral Vector-Mediated Suicide Gene Therapy

Background Glioblastoma is the most frequent and most malignant primary brain tumor with a poor prognosis. The translation of therapeutic strategies for glioblastoma from the experimental phase into the clinic has been limited by insufficient animal models, which lack important features of human tumors. Lentiviral gene therapy is an attractive therapeutic option for human glioblastoma, which we validated in a clinically relevant animal model. Methodology/Principal Findings We used a rodent xenograft model that recapitulates the invasive and angiogenic features of human glioblastoma to analyze the transduction pattern and therapeutic efficacy of lentiviral pseudotyped vectors. Both, lymphocytic choriomeningitis virus glycoprotein (LCMV-GP) and vesicular stomatitis virus glycoprotein (VSV-G) pseudotyped lentiviral vectors very efficiently transduced human glioblastoma cells in vitro and in vivo. In contrast, pseudotyped gammaretroviral vectors, similar to those evaluated for clinical therapy of glioblastoma, showed inefficient gene transfer in vitro and in vivo. Both pseudotyped lentiviral vectors transduced cancer stem-like cells characterized by their CD133-, nestin- and SOX2-expression, the ability to form spheroids in neural stem cell medium and to express astrocytic and neuronal differentiation markers under serum conditions. In a therapeutic approach using the suicide gene herpes simplex virus thymidine kinase (HSV-1-tk) fused to eGFP, both lentiviral vectors mediated a complete remission of solid tumors as seen on MRI resulting in a highly significant survival benefit (p<0.001) compared to control groups. In all recurrent tumors, surviving eGFP-positive tumor cells were found, advocating prodrug application for several cycles to even enhance and prolong the therapeutic effect. Conclusions/Significance In conclusion, lentiviral pseudotyped vectors are promising candidates for gene therapy of glioma in patients. The inefficient gene delivery by gammaretroviral vectors is in line with the results obtained in clinical therapy for GBM and thus confirms the high reproducibility of the invasive glioma animal model for translational research.

[1]  L. Molinero,et al.  Low-dose radiation enhances survivin-mediated virotherapy against malignant glioma stem cells. , 2008, Cancer research.

[2]  H. Immervoll,et al.  Oncolytic Herpes Simplex Virus Type-1 Therapy in a Highly Infiltrative Animal Model of Human Glioblastoma , 2008, Clinical Cancer Research.

[3]  Jian Wang,et al.  CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells , 2008, International journal of cancer.

[4]  A. Bergenheim,et al.  Adenoviruses 16 and CV23 efficiently transduce human low-passage brain tumor and cancer stem cells. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[5]  U. Himmelreich,et al.  Normal Brain Cells Contribute to the Bystander Effect in Suicide Gene Therapy of Malignant Glioma , 2007, Clinical Cancer Research.

[6]  Aleksandar Dakic,et al.  Tumor Growth Need Not Be Driven by Rare Cancer Stem Cells , 2007, Science.

[7]  H. Neumann,et al.  Bystander killing of malignant glioma by bone marrow-derived tumor-infiltrating progenitor cells expressing a suicide gene. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[8]  Alexander Brawanski,et al.  CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. , 2007, Cancer research.

[9]  H. Neumann,et al.  A retroviral packaging cell line for pseudotype vectors based on glioma‐infiltrating progenitor cells , 2007, The journal of gene medicine.

[10]  M. Lesniak,et al.  Convection enhanced drug delivery of novel therapeutic agents to malignant brain tumors. , 2007, Current drug delivery.

[11]  Mark W. Dewhirst,et al.  Glioma stem cells promote radioresistance by preferential activation of the DNA damage response , 2006, Nature.

[12]  I. Jonassen,et al.  Angiogenesis-independent tumor growth mediated by stem-like cancer cells , 2006, Proceedings of the National Academy of Sciences.

[13]  Yuri Kotliarov,et al.  Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. , 2006, Cancer cell.

[14]  Thomas C. Chen,et al.  Single-shot, multicycle suicide gene therapy by replication-competent retrovirus vectors achieves long-term survival benefit in experimental glioma. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[15]  P. Lønning,et al.  Widespread dispersion of adeno-associated virus serotype 1 and adeno-associated virus serotype 6 vectors in the rat central nervous system and in human glioblastoma multiforme xenografts. , 2005, Human gene therapy.

[16]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[17]  R. Henkelman,et al.  Identification of human brain tumour initiating cells , 2004, Nature.

[18]  H. Neumann,et al.  Selective transduction of malignant glioma by lentiviral vectors pseudotyped with lymphocytic choriomeningitis virus glycoproteins. , 2004, Human gene therapy.

[19]  D. Coil,et al.  Phosphatidylserine Is Not the Cell Surface Receptor for Vesicular Stomatitis Virus , 2004, Journal of Virology.

[20]  Ugo Orfanelli,et al.  Isolation and Characterization of Tumorigenic, Stem-like Neural Precursors from Human Glioblastoma , 2004, Cancer Research.

[21]  H. Schwalbe,et al.  Retroviral Vectors Pseudotyped with Severe Acute Respiratory Syndrome Coronavirus S Protein , 2004, Journal of Virology.

[22]  P. Bryant,et al.  Isolation and characterization of neural progenitor cells from post‐mortem human cortex , 2003, Journal of neuroscience research.

[23]  N. Rainov,et al.  Clinical Trials with Retrovirus Mediated Gene Therapy – what Have we Learned? , 2003, Journal of Neuro-Oncology.

[24]  Cynthia Hawkins,et al.  Identification of a cancer stem cell in human brain tumors. , 2003, Cancer research.

[25]  Thomas C Chen,et al.  Highly efficient and tumor-restricted gene transfer to malignant gliomas by replication-competent retroviral vectors. , 2003, Human gene therapy.

[26]  M. Westphal,et al.  Oncoretrovirus and Lentivirus Vectors Pseudotyped with Lymphocytic Choriomeningitis Virus Glycoprotein: Generation, Concentration, and Broad Host Range , 2002, Journal of Virology.

[27]  M. Westphal,et al.  Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. , 2001, Cancer research.

[28]  K. Ikenaka,et al.  Eradication of murine brain tumors by direct inoculation of concentrated high titer-recombinant retrovirus harboring the herpes simplex virus thymidine kinase gene , 2001, Gene Therapy.

[29]  W. Ostertag,et al.  Recombinant Expression of Lymphocytic Choriomeningitis Virus Strain WE Glycoproteins: a Single Amino Acid Makes the Difference , 2001, Journal of Virology.

[30]  N. Rainov.  A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. , 2000, Human gene therapy.

[31]  S. Ylä-Herttuala,et al.  Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses. , 2000, Human gene therapy.

[32]  A. Schambach,et al.  Context dependence of different modules for posttranscriptional enhancement of gene expression from retroviral vectors. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[33]  F. Cosset,et al.  Retroviral Vectors Pseudotyped with Lymphocytic Choriomeningitis Virus , 1999, Journal of Virology.

[34]  J. Nalbantoglu,et al.  Vesicular stomatitis virus G pseudotyped retrovector mediates effective in vivo suicide gene delivery in experimental brain cancer. , 1999, Cancer research.

[35]  M. Colombo,et al.  Eradication of rat malignant gliomas by retroviral-mediated, in vivo delivery of the interleukin 4 gene. , 1999, Cancer research.

[36]  F. Gage,et al.  In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector , 1996, Science.

[37]  R. Martuza,et al.  Attenuated multi–mutated herpes simplex virus–1 for the treatment of malignant gliomas , 1995, Nature Medicine.

[38]  J. Burns,et al.  A general method for the generation of high-titer, pantropic retroviral vectors: highly efficient infection of primary hepatocytes. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[39]  R. Bjerkvig,et al.  Multicellular tumor spheroids from human gliomas maintained in organ culture. , 1990, Journal of neurosurgery.

[40]  J. Markert,et al.  Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[41]  Mark Shackleton,et al.  Efficient tumour formation by single human melanoma cells , 2008 .

[42]  R. Bjerkvig,et al.  Expression of extracellular matrix components in a highly infiltrative in vivo glioma model , 2002, Acta Neuropathologica.